


Dear ACEMID Participant

Welcome to our ACEMID participant study newsletter. You are receiving this newsletter because you are currently enrolled or a past participant in the ACEMID research study. For previous versions of the newsletter, visit the ACEMID website [here](#).

Recruiting Momentum

Current recruitment: As of December 2025, we have enrolled over 8,963 participants across 15 study sites and have conducted more than 24,322 study visits. We're excited to have all 15 sites now operational.

For a list of active ACEMID sites see [here](#). Our updated target enrolment is 10,000 participants across all sites which we expect to recruit by mid 2026. We look forward to welcoming Mildura Base Public Hospital as the 16th ACEMID site, with work underway to install the 3D total body imaging system and commence recruitment by Mid-2026.



2026 Consumer Forum: Save the date

This year the annual ACEMID consumer forum will be held Friday April 24th, 2026, hosted by Monash University in Melbourne.

This will be a hybrid forum, allowing in-person and virtual attendance. More details and timings will be circulated soon.

Saliva sample update



Many of you have generously provided a saliva sample to help us better understand the genetics of melanoma. We are pleased to share that funding is now in place to begin analysing these samples and preparing results for participants.

Due to the large number of samples and the steps required to return results in an information booklet format, we expect results to be available in late 2026. We will share more information closer to the time, including how results can be accessed.

“Scarless” skin biopsy

Our team is testing “scarless biopsies” to help detect skin cancer, instead of traditional biopsies that involve cutting the skin. A gentle sticky skin tape is placed on a suspicious skin spot to collect the top layer of skin cells. These cells are then analysed to look for protein patterns that may help identify early signs of skin cancer. Selected individuals at the Princess Alexandra Hospital, Alfred Hospital and Westmead Hospital sites may have already been asked to participate in this sub-study.

In 2026 we will be expanding this collection into the regional, rural and remote sites, where participants may be asked to opt-in if they would like to contribute.

ACEMID's role in ongoing research studies

ACEMID is helping drive over 40 smaller studies. Each study adds an important piece to the bigger picture of skin cancer prevention and early detection. Discover how ACEMID is making a difference by exploring our [infographic here](#).

Continue to see your doctor for regular skin checks

As a reminder please note that ACEMID is a research study and does not replace your usual medical care. Please continue to see your medical practitioner for a clinical skin examination if you notice any changes on your skin, and continue your usual schedule of follow-up visits if this has been recommended by your doctor.

Thank you for your valuable participation in our research. Your support plays a crucial role in advancing our studies and making meaningful discoveries.

For enquires, please contact acemid@uq.edu.au

Funding Acknowledgement

This research program would not be possible without the funding from Australian Cancer Research Foundation (ACRF), National Health and Medical Research Council (NHMRC) and the Medical Research Future Fund (MRFF).